Context Therapeutics ( (CNTX) ) has shared an update.
Context Therapeutics Inc. has secured an exclusive, global license to develop, manufacture, and market two BioAtla Inc. antibodies, including an innovative Nectin-4 x CD3 T cell engaging bispecific antibody, with plans to file for investigational drug approval by mid-2026. BioAtla stands to receive an upfront payment of $11 million, up to $4 million in near-term milestones, and potentially an additional $118.5 million, along with sales royalties. This strategic move reinforces Context’s commitment to expanding its T cell engaging bispecific antibodies portfolio, aiming to address unmet needs in solid tumor treatments, while BioAtla continues to advance its own clinical programs.
For a thorough assessment of CNTX stock, go to TipRanks’ Stock Analysis page.
